Early detection remains one of the most important unmet needs in pancreatic ductal adenocarcinoma. Although outcomes can improve substantially when the disease is diagnosed at an earlier stage, many patients are still identified only after the cancer has progressed, when curative treatment is often no longer possible.
Current surveillance for individuals at increased risk of PDAC relies mainly on imaging, but interval cancers and advanced-stage diagnoses can still occur. This has created a need for complementary blood-based tools that may help support earlier detection in high-risk populations.
A new study evaluated PancreaSure, a five-biomarker serum signature based on TIMP1, ICAM1, CTSD, THBS1, and CA 19-9. The assay was originally developed to detect stage I and II PDAC in high-risk surveillance populations. In this analysis, investigators assessed whether PancreaSure could also reliably detect stage III and IV disease and how it performed in non–high-risk controls.
The original report, titled “Biomarker Panel Designed to Detect Early-Stage Pancreatic Ductal Adenocarcinoma Also Reliably Detects Advanced Disease,” was published in JCO Oncology Advances on June 9, 2026.
Authors: Erkut Borazanci, Jan Persson, Christian Pilarsky, Lise Lotte Gluud, Srdan Novovic, Arto Kokkola, Julie Earl, Kelly Hedger, Lisa Ford, Thomas King, Norma Palma, and Patricio M. Polanco.
Background
PDAC accounts for approximately 90% of pancreatic cancers and remains difficult to detect at a potentially curable stage. Survival differs substantially by stage, highlighting why earlier diagnosis remains a major priority.
PancreaSure was developed as a serum biomarker signature for use in high-risk individuals undergoing surveillance because of a pathogenic germline variant, family history of PDAC, and/or mucinous pancreatic cysts. The test is designed to be used alongside standard surveillance approaches and imaging, not as a replacement for them.
Before this study, PancreaSure had already been validated in two independent cohorts of patients with stage I and II PDAC and high-risk controls. The current analysis focused on its performance in stage III and IV PDAC and in individuals not known to be at high risk.
Read about Remission in Pancreatic Cancer on OncoDaily.
Study Design
This was a retrospective, blinded study of 619 serum samples. The cohort included 224 treatment-naïve patients with stage III or IV PDAC and 395 non–high-risk controls. The assay generated a positive or negative result using a predefined cutoff established during test development. The primary endpoint was sensitivity and specificity for distinguishing stage III and IV PDAC from non–high-risk individuals.
The study also compared these results with previous validation cohorts that had evaluated PancreaSure in stage I and II PDAC and high-risk controls.
Key Results
PancreaSure distinguished stage III and IV PDAC from non–high-risk controls with 87.9% sensitivity and 97.7% specificity. Performance was consistent across advanced stages, with 86.7% sensitivity in stage III disease and 89.1% sensitivity in stage IV disease. The assay showed higher sensitivity than CA 19-9 alone in stage III and IV PDAC:
- PancreaSure: 87.9%
- CA 19-9 alone: 77.2%
Specificity was similar between PancreaSure and CA 19-9 alone. When compared with previous early-stage validation cohorts, PancreaSure showed significantly higher sensitivity in stage III and IV disease than in stage I and II disease:
- Stage I and II PDAC: 77.3%
- Stage III and IV PDAC: 87.9%
Across stages I to IV combined, PancreaSure detected PDAC with 80.6% sensitivity, although the confidence interval was wide because the analysis pooled data from different cohorts. Specificity also differed by control population. PancreaSure achieved 97.7% specificity in non–high-risk controls compared with 92.2% specificity in high-risk controls.
Clinical Interpretation
These findings suggest that PancreaSure can detect advanced PDAC with high sensitivity and specificity, despite being developed primarily for early-stage detection in high-risk surveillance populations.
PancreaSure is not intended to replace imaging or biopsy. Its role remains complementary to standard surveillance and diagnostic approaches.
The test is not recommended for patients who already have imaging evidence of advanced pancreatic cancer, because it would not add meaningful diagnostic information in that setting. It may be administered to symptomatic patients, but results alone should not be used to establish a diagnosis.
Limitations
The retrospective design limited the availability of complete demographic and clinical data. For controls, clinical information was limited beyond negative HIV, HBsAg, and HCV status. Most patients with advanced PDAC did not have detailed information on family history, pathogenic germline variants, or mucinous pancreatic cysts, which limited comparisons between sporadic PDAC and PDAC occurring in high-risk individuals.
Cases were older than controls, and there was a male predominance among patients with PDAC. Previous validation studies suggested that age and sex imbalance had limited impact on test performance, but these differences remain relevant when interpreting the findings.
Further validation and follow-up studies are needed to better define how PancreaSure could be used beyond its intended surveillance setting, including treatment response, recurrence, and disease progression monitoring.
Takeaway
PancreaSure, a five-biomarker serum signature developed for early detection of PDAC in high-risk individuals, also showed strong performance in advanced disease. In this retrospective blinded study, the assay detected stage III and IV PDAC with 87.9% sensitivity and 97.7% specificity.
These findings broaden understanding of PancreaSure’s performance across PDAC stages, while reinforcing that its clinical role remains complementary to imaging and other diagnostic tools.